Introduction
Home use of volatile organic chemical (VOC)-contaminated tap water commonly results in exposure by multiple routes. Previously, toxicity/carcinogenicity risk assessments focused primarily on the amount of chemical in the water ingested. It is now recognized that inhalation during showering and other water-use activities also contributes significantly to one's systemically absorbed dose (Gordon et al., 2006; Weisel and Jo, 1996) . There is little information, however, on the relative quantities and toxicities of VOCs absorbed from different portals. Health risk assessments of ingested VOCs must often be conducted on the basis of inhalation toxicity data, with direct extrapolation from one route of exposure to another. Also, oral cancer and non-cancer studies of VOCs in rodents have usually employed daily gavage dosing. The relevance of these single bolus data to human risks is questionable, as people typically consume contaminated water in small, divided doses over the course of the day.
1,1-Dichloroethylene (DCE) was selected for the current study. It is used primarily as a chemical intermediate and in the production of polyvinylidene copolymers utilized to produce flexible films (e.g., Saranwrap ® , Velon ® ) for food packaging. Environmental releases occur primarily by evaporation, though some DCE is released to soil, groundwater and surface waters. DCE is also formed by biotic and abiotic degradation of common VOCs including 1,1,1-trichloroethane (TRI), trichloroethylene (TCE) and perchloroethylene (PERC) (ATSDR, 1994) .
These are the most frequently found organic chemicals in groundwater in the proximity of hazardous waste sites (Fay, 2006) and in drinking water in the U.S. (Moran et al., 2007) .
Exposure to low levels of DCE in environmental media is of concern, largely because of the VOC's cytotoxic and carcinogenic potential. The primary target organs of DCE are the liver, lungs and kidneys (ATSDR, 1994; IRIS, 2002) . Maltoni et al. (1985) describe significant This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 3, 2010 as DOI: 10.1124 at ASPET Journals on April 27, 2017 jpet.aspetjournals.org Downloaded from increases in kidney adenocarcinomas (males) and pulmonary adenomas (both sexes combined) in Swiss mice inhaling 25 ppm DCE for 1 year. Lee et al. (1978) also report an increased incidence of pulmonary adenomas in male CD-1 mice inhaling 55 ppm DCE for a year, but not in rats. No tumors due to DCE were seen in Sprague-Dawley (S-D) rats that inhaled up to 75 ppm for 18 months (Quast et al., 1986) . The species and gender specificity of the renal tumors and cytotoxicity were attributed by Speerschneider and Dekant (1995) to higher expression of cytochrome P450IIE1 (CYP2E1), resulting in greater bioactivation of DCE in kidneys of male mice. Quast et al. (1983) supplied male and female S-D rats with drinking water containing up to 200 ppm DCE (daily dose = 20 -30 mg/kg) for 2 years. There were no exposure-related neoplastic changes. Ponomarkov and Tomatis (1980) , however, observed a modest increase in liver adenomas and carcinomas in rats gavaged once weekly with 50 mg/kg of the chemical.
Thus, it appears that DCE's toxicity and carcinogenicity potential are species-and genderdependent, and influenced significantly by route of exposure and oral dosage regimen as well.
Toxicokinetic (TK) studies can provide insight into the influence of exposure route and dosage regimen on DCE's target organ dosimetry and resulting toxic/carcinogenic potential.
VOCs absorbed from the gastrointestinal (GI) tract are subject to first-pass elimination by the liver and lungs. In contrast, inhaled VOCs directly enter the arterial circulation and should be rapidly delivered to organs in relatively large amounts. Lee et al. (1996) demonstrated in rats that the liver and lungs, acting in concert, removed up to 60% of low doses of TCE. Liu et al. (2009) subsequently found that oral bioavailability was just ~ 12 -16% in rats given 100 µg TCE/kg, an environmentally-relevant dose. DCE should also be efficiently removed, as it is also extensively metabolized and is more volatile than TCE. Although gavage dosing has commonly been utilized for sake of convenience in chronic toxicity and cancer bioassays of VOCs, this can This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 3, 2010 as DOI: 10.1124 at ASPET Journals on April 27, 2017 jpet.aspetjournals.org Downloaded from result in such a rapid rate of delivery to the liver that cytotoxicity may occur and much of the absorbed dose avoids first-pass metabolism (Lee et al., 2000) . Thus, it might be anticipated that administration of DCE by gavage will result in more pronounced damage of the liver and extrahepatic organs than will administration of the same total amount in divided doses.
The overall objective of the current investigation was to characterize the effects of exposure route and oral dosage regimen (bolus versus prolonged gastric infusion) on the bioavailability and hepatorenal toxicity of DCE in rats. Experiments were designed to test the following hypotheses: a) Administration of equivalent oral and inhaled doses of DCE will result in significantly different internal doses, with more pronounced differences at lower dosagelevels; b) Inhalation will result in higher arterial DCE levels and greater extrahepatic (i.e., renal injury) than ingestion; c) Consumption of DCE as an oral bolus will result in higher arterial concentrations, as well as more severe liver and kidney damage, than will repetitive ingestion of the same total dose over an extended period.
Methods
Chemicals. 1,1-Dichloroethylene (DCE) of 99% purity was purchased from Aldrich Chemical Co. (Milwaukee, WI). The purity was verified by gas chromatography. All other chemicals and biochemicals were obtained from Sigma Chemical Co (St. Louis, MO). Acepromazine hydrochloride and ketamine hydrochloride were purchased from Fort Dodge Laboratories (Fort Dodge, IA). Bayer Corporation (Shawnee Mission, KS) supplied xylazine hydrochloride.
Animals. Male Sprague-Dawley (S-D) rats were obtained from Charles River Breeding
Laboratories (Raleigh, NC) and maintained on a 12-h light/dark cycle, with light from 7 AM to 7
This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 3, 2010 as DOI: 10.1124 at ASPET Journals on April 27, 2017 jpet.aspetjournals.org Downloaded from PM. They were housed in groups of 3 in stainless steel wire mesh cages in a negative air-flow animal rack. The rack was kept in a biohazards facility in an AAALAC-approved facility. The rats were maintained in a temperature (25° C)-and humidity (40%)-controlled room for at least 1 week prior to use. Tap water and food (Purina Rat Chow 5001 ® , Purina, St. Louis, MO) were available ad libitum during this acclimation period. Body weights at the time of the TK and toxicity experiments were 325-375 g and 140-150 g, respectively. The larger rats were necessary for inhalation experiments and for serial micro blood sampling protocols. The experimental protocols were reviewed and approved by the University of Georgia Animal Care Committee.
Animal Preparation. All rats were surgically cannulated for the TK experiments. Each animal was anesthetized by i.m. injection of 0.1 ml/100 g b.w. of a "cocktail" consisting of ketamine hydrochloride (100 mg/ml), acepromazine maleate (10 mg/ml), and xylazine hydrochloride (20 mg/ml) (3:2:1, v:v:v). An indwelling cannula (PE-50 polyethylene tubing) was implanted into the right carotid artery of each rat. The cannula was inserted into the artery toward the heart until the tip rested just above the aortic arch. The tubing was then securely ligated to the vessel.
A second cannula was placed in the right jugular vein of some rats for i.v. dosing. For gastric (g.i.) infusion experiments, a ventral incision was made in the abdominal wall, and a flare-tipped cannula implanted into the fundus of the stomach. All cannulas were passed under the skin and exteriorized at the nape of the neck, so the animals could move about freely without disturbing the cannulas upon recovery. Water was provided, but food was withheld during the 24-h postsurgical recovery period before dosing. Although fasting alone resulted in increased liver CYP2E1 activity, fasted S-D rats on which cannulation surgery was performed exhibited CYP2E1 activity similar to that of non-fasted controls (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. Inhalation Exposures. Exposures to DCE were conducted as described by Dallas et al. (1989) .
Each cannulated rat was placed into a restraining tube (Battelle-Geneve, Switzerland) of the type used for nose-only exposures. A face mask with a miniaturized one-way breathing valve (Hans Rudolph Inc., St. Louis, MO) was secured to the animal's head with elastic straps. The mask was designed to fit 300-to 400-g rats, so that the valve entry port was immediately adjacent animal's nares and valve dead space was minimized. The valve included sampling ports, so the concentration of DCE in the separate inhaled and exhaled breath streams could be monitored.
Desired concentrations of DCE were generated in a 70-L gas sampling bag (Calibrated Instruments, Ardsley, NY). The bag was connected in series by Teflon ® tubing to a pneumotachograph, the breathing valve, and an empty 70-L gas collection bag. Each rat was acclimated to the mask and restraining tube for 1 h until stable breathing patterns were established. Two-h exposures to 100 or 300 ppm DCE were initiated between 10:00 AM and 12:00 PM. Serial breath and micro blood samples were taken during and up to 3 h post exposure for DCE analysis.
Respiratory Measurements. The airflow created by an animal's inspiration was recorded, so the minute volume (V E ), respiratory rate (f), and tidal volume (V T ) could be determined during and following the inhalation exposures. A mean value for these parameters was obtained for each rat by averaging measurements made at 10-min intervals. Mean values (± S.D.) (n = 6) for the 2-h, 100-ppm inhalation sessions were: V E = 230 ± 18 ml/min; f = 136 ± 6 breaths/min; and V T = 1.7 ± 0.2 ml. Mean values (± S.D.) (n = 6) for 2-h, 300-ppm sessions were: V E = 216 ± 37 ml/min; f = 135 ± 23 breaths/min; and V T = 1.6 ± 0.2 ml. (Alltech Associates, Deerfield, IL). Operating temperatures were: 150° C, injection port; 360° C, ECD; and 70° C, column oven. The nitrogen (carrier gas) flow rate was 40 ml/min, with an additional make-up gas flow rate of 30 ml/min to the detector.
Blood DCE levels were quantified by GC headspace analysis. The volume of blood taken at a given sampling time depended upon the anticipated DCE concentration. Ten-to 100-µl samples were transferred to chilled headspace vials, which were immediately capped with a polytetrafluoroethylene-lined septum and tightly crimped. The vials were placed into the HS-6
headspace autosampler of a Sigma 300 GC (Perkin-Elmer, Norwalk, CT), equipped with an electron capture detector and a 8-ft x ⅛ -in stainless steel column packed with FFAP Chromasorb W-AW (80-100 mesh) (Alltech Associates, Deerfield, IL). Operating temperatures were: 200° C, injection port, 360° C, ECD; and 70° C, column oven. The carrier gas was 5% argon-methane at a flow rate of 40 ml/min, with a make-up gas flow rate of 20 ml/min to the ECD.
Toxicity Experiments. The objectives of these experiments were to elucidate the hepatorenal toxicity of inhaled and ingested DCE and to determine the effect of oral dosage regimen on liver and kidney injury. The higher exposure levels (i.e., 300 ppm and 30 mg/kg) employed in the TK studies were utilized. Fasted male S-D rats of 140 to 150 g were selected for this particular experiment, since Andersen and Jenkins (1977) found older rats were much less susceptible to DCE-induced hepatotoxicity, and that fasting markedly increased the severity of liver injury.
Use of rats as the animal model necessitated these measures to enhance DCE toxicity, as rats metabolically activate less of the chemical than mice and are less susceptible to it (Dowsley et al., 1995) .
Groups of 140-to 150-g male S-D rats were subjected to: (a) 300 ppm DCE vapors animals were maintained individually in a 26.5-L glass chamber equipped with a small fan. The chamber had a port for introduction of DCE and for withdrawal of air samples. These samples were taken every 10 min during the 2-h exposures, and their DCE content measured by a GC with a flame ionization detector. The chamber concentration (± S.E., n = 8) decreased gradually from 306 ± 11 ppm at the beginning of the session to 238 ± 13 ppm at the end of the 2 h. As in the TK experiments, orally-administered DCE was incorporated into a 5% aqueous Alkamuls ® emulsion and given in a total volume of 5 ml/kg p.o. or g.i. Controls received 5 ml saline/kg p.o.
Blood was taken from the tail artery at 2 h and by cardiac puncture 24 h post dosing for measurement of sorbitol dehydrogenase (SDH) activity by a standard spectrophotometric procedure.
A second subset of rats was kept for evaluation of urinary enzyme excretion over two successive 12-h periods after conclusion of the DCE exposure regimens. These animals were maintained in Nalgene ® plastic metabolism cages for collection of 12-and 24-h urines over ice. 
Results
Inhalation. The target chamber concentrations for the DCE inhalation exposures in the kinetics experiments were 100 and 300 ppm. The actual concentrations inhaled by the animals were determined by analyses of air samples taken from sampling ports immediately adjacent to the animal's miniaturized breathing valve. The inhaled DCE concentrations for the 6 rats in each group at the initiation of exposures were 101.6 ± 0.8 and 310.0 ± 3.5 ppm (mean ± S.E.) for the 100-and 300-ppm groups, respectively.
Blood concentration versus time profiles revealed that inhaled DCE was rapidly absorbed into and eliminated from the body (Fig. 1) . Inhaled DCE was readily available for distribution to body tissues, in that arterial blood concentrations were > 50% of near steady-state at the first sampling time (i.e., 2 min). Blood concentrations in the 100-and 300-ppm groups reached near equilibrium within 10 to 15 min, and increased asymptotically for the duration of the 2-h exposures (Figs. 1A and B) . The C max , AUC 2 0 and AUC ∞ 0 values increased 4.7-, 3.9-and 3.9-fold, respectively, as the inhaled concentration increased from 100 to 300 ppm (Table 1) . DCE concentrations in the exhaled breath exceeded alveolar concentrations during the inhalation exposures, due to the contribution of unabsorbed DCE in the respiratory dead space (Fig. 1) .
The converse was true post exposure. Exhaled breath levels were relatively low, due to dilution with fresh air residing in the dead space. Alveolar and exhaled breath levels of DCE exhibited a biexponential decline post exposure, with initial precipitous drops. The terminal elimination half-lives for the 100-and 300-ppm groups were both 50 min (Table 1) .
Systemically-absorbed doses of DCE were determined from the inhalation data.
Subtraction of the quantity of DCE exhaled from that inhaled, with allowance for dead space, yielded the amount and percentage of chemical taken up each sampling time. Percentage systemic uptake diminished somewhat during the first 20 min, due to increase in DCE content in the body and returning pulmonary blood. Thereafter, uptake remained relatively constant at 65 -72% at near steady-state (Fig. 2) . Uptake appeared to be largely independent of exposure level during the 2-h sessions, as the 100-and 300-ppm values did not differ significantly from one another at any sampling time. Cumulative uptake over the 2-h exposures could be determined by summing of uptake for each time-period and by monitoring respiratory minute volume.
Cumulative systemic uptake is plotted against duration of exposure in Fig. 3 . The mean (± S.D.) total systemically absorbed doses at 2 h in the 100-and 300-ppm groups were 9.7 ± 0.9 and 29.7
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Exposure Route.
Ten and 30 mg DCE/kg were administered over 2 h by g.i. and the arterial blood time-courses contrasted with their corresponding inhalation profiles, in order to elucidate the influence of route of exposure on internal dosimetry. It is obvious in Fig. 4 that the pattern of systemic uptake and elimination for each g.i. group was quite different from that for its corresponding inhalation group. Blood DCE levels progressively increased during the 2 h infusions and then declined at a slow rate post exposure relative to the inhalation groups' levels.
As a result, AUC
∞ 0 values for the respective 300-ppm inhalation and 30 mg/kg g.i. groups did not differ significantly (Table 1 ). The AUC 2 0 and C max values for the inhalation group, however, were substantially higher. Similar dosimetry relationships were manifest at the lower exposure level, though differences in the route-dependent kinetic parameters were more pronounced (Table 1) .
Oral Dosage Regimen.
The influence of oral dosage regimen on the TK of DCE was evaluated by comparing arterial blood profiles of the p.o. and g.i. groups (Fig. 5) . DCE was rapidly absorbed after it was given as an oral bolus. Blood levels were maximal within 5 to 7 min. With the 3-fold increase in bolus dose, there were 4-, 5-and 4.6-fold increases in C max , The TK of DCE was not dose-dependent in the i.v. dosage range studied here. Ten and 30 mg DCE/kg were injected i.v. as a reference to determine bioavailability. The blood concentration profiles are shown in Fig. 6 . An initial rapid drop in blood levels is followed by a relatively slow decline. There were no changes with dose in clearance or in half-life during the distribution phase (α) or the terminal elimination phase (β) ( Table 2 ). There was a 2.6-fold increase in AUC ∞ 0 with the 3-fold increase in dosage. Half-life did not vary significantly with dose, irregardless of oral dosage regimen or route of exposure (Table 1) . Clearance did not vary significantly with dose, though it did tend to be lower in the 10 mg/kg groups for each of the three exposure scenarios (data not shown). Bioavailability (F) was also consistently lower in each instance at the lower dose (Table 1) . First-pass hepatic and pulmonary elimination was clearly most efficient in the 10 mg/kg g.i. group (F = 17%), in which the liver was presented with the lowest DCE levels at the slowest rate. The elimination rate constants (K 12 and K 21 ) indicated a rapid transfer from blood to tissues, followed by a slower release from tissues back to blood (Table 2) .
Toxicity.
The extent of liver damage by DCE was influenced substantially by the oral dosage regimen, though only slightly by the exposure route. All three modes of administration produced statistically significant increases in serum SDH activity over controls 2 and 24 h after dosing (Fig. 7) . Interestingly, the pronounced elevation at 2 h in the gavaged rats was followed by only a modest rise at 24 h. This pattern suggests rapid damage of the more susceptible hepatocytes. The phenomenon was not exhibited by the other exposure groups. SDH activity in rats inhaling DCE was modestly higher than in the g.i. rats 2 and 24 h post exposure.
The route dependence of kidney injury by DCE was quite different from that of the liver.
Urinary GGT excretion was markedly elevated over controls in rats that inhaled 300 ppm DCE This article has not been copyedited and formatted. The final version may differ from this version. for 120 min (Fig. 8A) . The amounts of GGT eliminated during each 12-h period post exposure were comparable. Urinary GGT amounts were not elevated over controls 12-or 24-h post exposure in animals dosed by gavage or g.i. Exposure route-and time-dependent changes in urinary NAG excretion largely paralleled the changes in GGT, the other brush border enzyme (Fig. 8B) . There appeared to be modest increases over controls in urinary excretion of NAG in the g.i. group at 12 and 24 h, but the apparent increases were not sufficient to be statistically significant. Administration of DCE as an oral bolus did not enhance GGT or NAG excretion over that in controls or the g.i. group.
Discussion
There is a paucity of TK data relevant to route-to-route and dosage regimen-to-regimen extrapolations. Few study protocols have included comparable exposures of rodents to a VOC orally and by inhalation. In such cases the test chemical has typically been administered over different time-frames (e.g., inhalation for several h versus ingestion of a single bolus).
Systemically-absorbed doses have rarely been determined for inhalation exposures. Our experimental approach was unique, in that it involved administration of equivalent doses of chemical over the same time-frame by inhalation and g.i. This seemed a logical approach to a rather complex problem, namely comparing the kinetics and toxicity of a chemical entering the systemic circulation at different locations from different portals at different rates.
Findings in the present study demonstrate that route of exposure has a significant effect on the TK of DCE. The lungs are an optimal site for absorption of DCE and other VOCs, due to their relatively large surface area, high blood perfusion rate and intimate alveolar-capillary interfaces (Bruckner et al., 2008) . Rapid, extensive absorption of DCE into the arterial (Table 2) , which is apparently more efficiently removed by the liver. Lee et al. (1996) report that presystemic elimination of TCE in rats is inversely proportional to dose in this dosage range.
Route of administration had a pronounced influence on the extent of kidney injury by the higher DCE dosage used in the current study. The kidneys were subjected for 2 h to relatively large quantities of the chemical during inhalation of 300 ppm (Fig. 4) , due to the elevated arterial concentrations (2 -3 µg/ml) and the high rate of renal blood flow. Jackson and Conolly (1985) observed increases in kidney/b.w. ratio and in serum urea nitrogen and creatinine, as well as morphological changes in the renal cortex of fasted male S-D rats that inhaled ≥ 250 ppm DCE for 4 h. It is worthy of note in the current study that the exposure route had an even greater effect on TK at the lower dosage, where nephrotoxicity was not evaluated.
DCE is biotransformed by CYP2E1 in rodents to at least three reactive metabolites: DCE epoxide; 2-chloroacetyl chloride; and 2,2-dichloroacetaldehyde. Forkert (2001) and Simmonds et al. (2004) conclude from studies of mouse liver and lung that DCE epoxide is the most important cytotoxic metabolite. Dowsley et al. (1999) also find CYP2E1-mediated DCE epoxide formation in human liver and lung microsomes. Martin et al. (2003) damage hepatocytes (Jones and Liebler, 2000) and renal tubular cells (Brittebo et al., 1993) by binding covalently to their proteins and nucleic acids. DCE cytotoxicity and covalent binding are greatest in murine cells with the highest CYP2E1 content, namely centrilobular hepatocytes, bronchiolar Clara cells and renal proximal tubular cells (Forkert, 2001; Speerschneider and Dekant, 1995) . Cummings et al. (2001) report higher CYP2E1 content in proximal than in distal tubular cells in kidneys of male F344 rats. Nephrotoxicity in the present study was evidenced by urinary excretion of large amounts of brush border enzymes.
The hepatic glutathione (GSH)/renal β -lyase biotransformation pathway plays a major role in the nephrotoxicity and carcinogenicity of halocarbons such as TCE and PERC, though this is not the case for DCE (Dekant, 1996) . DCE epoxide and 2-chloroacetyl chloride are detoxified by GSH conjugation and hydrolysis, respectively. GSH affords cells protection until DCE metabolites are formed in quantities sufficient to deplete the tripeptide (Brittebo et al., 1993; Forkert, 2001 ). 2,2-Dichloroacetaldehyde, a minor metabolite of DCE in mouse liver microsomes that undergoes GSH conjugation and subsequent metabolism by renal β -lyase, has not been detected in vivo (Forkert, 2001 ).
There are very few experimental data available with which to contrast the TK of a VOC ingested in divided doses with that when the total dose is given as a single oral bolus. Internal, or systemically-absorbed doses are usually unknown when VOCs are consumed in water. The intersubject rate and pattern of ingestion vary widely in different circumstances. Under the exposure condition (i.e., 2-h constant gastric infusion) selected for the current investigation, arterial blood levels progressively rise for the 2 h. The levels never approach the bolus C max , but remain elevated longer. apparently produce hepatocellular concentrations that exceed the capacity of the cells' detoxification (e.g., GSH conjugation) and repair mechanisms.
There have been a number of instances in which adverse effects of VOCs ingested in divided doses were very different from those seen in experiments employing oral bolus dosing.
Chloroform (CHC1 3 ), 1, 1-and 1, 2-dichloroethane have produced a high incidence of hepatocellular carcinoma when administered to B6C3F1 mice by gavage. Jorgenson et al. (1985) and Klaunig et al. (1986) found no evidence of hepatic tumors when comparable doses were supplied in the animals' drinking water. Larson et al. (1994) and Coffin et al. (2000) found CHC1 3 to enhance hepatocellular proliferation and/or to decrease methylation of the promoter region of the c-myc gene in mouse liver when given by gavage. Little if any change occurred in mice ingesting equivalent daily doses of the chemical in water ad libitum. La et al. (1996) measured greater DNA binding and cellular proliferation in the liver, kidney and forestomach of male B6C3F1 mice gavaged with 1, 2, 3-trichloropropane than in mice receiving the halocarbon in drinking water. The latter research groups did not conduct TK experiments, but it is quite likely their and the other dissimilar responses to the disparate dosage regimens were attributable to substantial differences in target organ dosimetry. Use of results from gavage studies are thus likely to often substantially overestimate toxic and carcinogenic risks to the liver of VOCs in food or drinking water.
In conclusion, findings in the current investigation illustrate that basic features of experimental designs of toxicology studies of VOCs can substantially alter the chemicals' TK, This article has not been copyedited and formatted. The final version may differ from this version. 
FIGURE LEGENDS
1. Time-courses of DCE concentrations in exhaled breath (•), alveolar air ( о ) and arterial blood (♦) of rats inhaling 100 (A) and 300 (B) ppm DCE for 120 min, followed by a 180-to 210-min post exposure period. Each point and brackets represent the mean ± S.D. for 6 rats.
2.
Percentage systemic uptake of DCE during 120 min of inhalation of 100 or 300 ppm DCE. Each point and brackets represent mean ± S.D. for 6 rats.
3.
Cumulative systemic uptake of DCE during inhalation of 100 or 300 ppm DCE for 120 min. Each point represents the mean ± S.D. for 6 rats. The connecting lines are drawn point to point.
4.
Effect of exposure route on arterial blood DCE concentration time-courses. One group of rats inhaled 100 ppm DCE for 120 min, while another group received an equivalent dose of 10 mg DCE/kg by constant gastric infusion (g.i.) over a 120-min period (A). Other groups of rats were similarly exposed to 300 ppm and 30 mg/kg (B). Brackets encase mean ± S.D. for groups of 6 rats.
5.
Influence of oral dosage regimen on arterial blood DCE concentration time-courses. In A, rats were given 10 mg DCE/kg as an aqueous emulsion by gavage (p.o.) or by constant gastric infusion (g.i.) over 120 min. In B, rats were similarly administered 30 mg/kg. Brackets encase mean ± S.D. for groups of 6 rats. (mg/L) (min) (min) (µg-min/ml) (µg-min/ml) (%) (ppm) inhal 10 p.o.
2.2 ± 0.8 This article has not been copyedited and formatted. The final version may differ from this version.
